Current pharmaceutical design, ‎1381-6128

Journal

Publications

  1. 2017
  2. E-pub ahead of print

    A comprehensive review of mTOR-inhibiting pharmacotherapy for the treatment of non-infectious uveitis

    Robert Barry, David Moore & Alastair Denniston, 11 Jan 2017, (E-pub ahead of print) In: Current pharmaceutical design. 23, 46

    Research output: Contribution to journalArticlepeer-review

  3. 2016
  4. Published

    Lipid based nanosystems for curcumin: Past, present and future

    Tom Mills & Ian Norton, 1 Aug 2016, In: Current pharmaceutical design. 22, 27, p. 4247-4256 10 p.

    Research output: Contribution to journalReview articlepeer-review

  5. Published

    The production of solid dosage forms from non-degradable polymers

    Christopher McConville, 1 May 2016, In: Current pharmaceutical design. 22, 19, p. 2738-2760 23 p.

    Research output: Contribution to journalArticlepeer-review

  6. 2015
  7. Published

    Controversies in the pharmacological treatment of uveitis

    Robert Barry & Alastair Denniston, 30 Oct 2015, In: Current pharmaceutical design. 21, 32, p. 4682-4687 6 p.

    Research output: Contribution to journalArticlepeer-review

  8. Published

    Double point modified analogs of vitamin D as potent activators of vitamin D receptor

    Geoff Brown & , 1 Mar 2015, In: Current pharmaceutical design. 21, 13, p. 1741-1763 23 p.

    Research output: Contribution to journalArticlepeer-review

  9. Published

    Best practice for atrial fibrillation patient education

    Deirdre Lane, & Gregory Lip, 2015, In: Current pharmaceutical design. 21, 5, p. 533-43 11 p.

    Research output: Contribution to journalReview articlepeer-review

  10. 2012
  11. Published
  12. Published
  13. Published
  14. Published

    Philosophical issues in the prodromal phase of psychosis

    Matthew Broome & , 1 Jan 2012, In: Current pharmaceutical design. 18, p. 596-605 10 p.

    Research output: Contribution to journalArticlepeer-review

Previous 1 2 3 4 Next